Advertisement

Topics

Novartis Gets FDA Approval For Cosentyx Label Update - Quick Facts

01:34 EST 8 Feb 2018 | RTTNews

Swiss drug major Novartis AG (NVS) said that the U.S. Food and Drug Administration or FDA has approved a label update for Cosentyx or secukinumab, the first interleukin-17A or IL-17A inhibitor approved to treat moderate-to-severe plaque psoriasis.

Original Article: Novartis Gets FDA Approval For Cosentyx Label Update - Quick Facts

NEXT ARTICLE

More From BioPortfolio on "Novartis Gets FDA Approval For Cosentyx Label Update - Quick Facts"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...